5-fluoro-2-(6-fluoro-2-methyl-1H-benzimidazol-1-yl)-N-[4-(trifluoromethyl)phenyl]pyrimidine-4,6-diamine manufacturers
- Unesbulin
-
- $89.00
-
2026-06-02
- CAS:1610964-64-1
- Purity: 98.71%
- Supply Ability: 10g
- Unesbulin
-
- $89.00
-
2026-06-02
- CAS:1610964-64-1
- Purity: 98.71%
- Supply Ability: 10g
|
| | 5-fluoro-2-(6-fluoro-2-methyl-1H-benzimidazol-1-yl)-N-[4-(trifluoromethyl)phenyl]pyrimidine-4,6-diamine Basic information |
| Product Name: | 5-fluoro-2-(6-fluoro-2-methyl-1H-benzimidazol-1-yl)-N-[4-(trifluoromethyl)phenyl]pyrimidine-4,6-diamine | | Synonyms: | 5-fluoro-2-(6-fluoro-2-methyl-1H-benzimidazol-1-yl)-N-[4-(trifluoromethyl)phenyl]pyrimidine-4,6-diamine;PTC596;5-Fluoro-2-(6-fluoro-2-methyl-1H-benzo[d]imidazol-1-yl)-N4-(4-(trifluoromethyl)phenyl)pyrimidine-4,6-diamine;4,6-Pyrimidinediamine, 5-fluoro-2-(6-fluoro-2-methyl-1H-benzimidazol-1-yl)-N4-[4-(trifluoromethyl)phenyl]-;5-Fluoro-2-(6-fluoro-2-methyl-1H-benzoimidazol-1-yl)-N-(4-trifluoromethylphenyl)-pyrimidine-4,6-diamine;Unesbulin (Synonyms: PTC596);integration,p53,Moloney,murine,leukemic,orally,virus,G2/M,BMI-1,Inhibitor,APC/CCDC20,Apoptosis,Unesbulin,inhibit,PTC 596,leukemia,PTC-596,AML;Unesbulin (PTC596) | | CAS: | 1610964-64-1 | | MF: | C19H13F5N6 | | MW: | 420.34 | | EINECS: | | | Product Categories: | | | Mol File: | 1610964-64-1.mol | ![5-fluoro-2-(6-fluoro-2-methyl-1H-benzimidazol-1-yl)-N-[4-(trifluoromethyl)phenyl]pyrimidine-4,6-diamine Structure](CAS/20180703/GIF/1610964-64-1.gif) |
| | 5-fluoro-2-(6-fluoro-2-methyl-1H-benzimidazol-1-yl)-N-[4-(trifluoromethyl)phenyl]pyrimidine-4,6-diamine Chemical Properties |
| Boiling point | 583.9±60.0 °C(Predicted) | | density | 1.55±0.1 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | DMF:30.0(Max Conc. mg/mL);71.4(Max Conc. mM)
DMSO:30.0(Max Conc. mg/mL);71.4(Max Conc. mM)
Ethanol:5.0(Max Conc. mg/mL);11.9(Max Conc. mM) | | form | A crystalline solid | | pka | 2.65±0.10(Predicted) | | color | White to off-white |
| | 5-fluoro-2-(6-fluoro-2-methyl-1H-benzimidazol-1-yl)-N-[4-(trifluoromethyl)phenyl]pyrimidine-4,6-diamine Usage And Synthesis |
| Uses | Unesbulin (PTC596) is an orally active and selective B-cell-specific Moloney murine leukemia virus integration site 1 (BMI-1) inhibitor. Unesbulin downregulates MCL-1 and induces p53-independent mitochondrial apoptosis in acute myeloid leukemia (AML) cells. Unesbulin has anti-leukemic activity[1][2]. | | in vivo | Unesbulin (PTC596; 5 mg/kg; oral gavage; every 3 days for 13 days) significantly prolongs mouse survival[1].
Unesbulin (20 mg/kg; oral gavage; once a week for 15 days) causes tumor volume significantly smaller than that of control SCID mice with K562 cells[1].
Unesbulin (10 or 12.5 mg/kg; oral gavage; twice a week until death) causes the survival significantly longer than the vehicle-treated group in NOD-SCID mice with HL-60 cells[1].
| Animal Model: | NOD-SCID/IL2Rγ-KO (NSG) mice with MOLM-13 cells[1] | | Dosage: | 5mg/kg | | Administration: | Oral gavage; every 3 days for 13 days | | Result: | Significantly prolonged mouse survival compared with the vehicle-treated mice in a dose-dependent manner.
|
| | References | [1] Nishida Y, et al. The novel BMI-1 inhibitor PTC596 downregulates MCL-1 and induces p53-independent mitochondrial apoptosis in acute myeloid leukemia progenitor cells. Blood Cancer J. 2017 Feb 17;7(2):e527. DOI:10.1038/bcj.2017.8
[2] BMI1 inhibitor PTC596 |
| | 5-fluoro-2-(6-fluoro-2-methyl-1H-benzimidazol-1-yl)-N-[4-(trifluoromethyl)phenyl]pyrimidine-4,6-diamine Preparation Products And Raw materials |
|